HQ
  • About A*STAR
    • Corporate Profile
      • A*STAR Board Members
      • Senior Management
      • Organisation Structure
      • Corporate Social Responsibility
      • Diversity at A*STAR
      • A*STAR Sustainability
    • Annual Report
    • A*STAR Global Network
  • Research
    • About A*STAR Research
    • Funding Opportunities
    • S-SEAF
    • Research Ethics
    • Biomedical Research Council
    • Science and Engineering Research Council
    • Our People
      • Highly Cited Researchers
      • Honours and Accolades
  • Innovation & Enterprise
    • About I&E
    • Innovation Offerings
  • Scholarships
  • News
    • A*STAR News
      • Publicity Highlights
      • Press Releases
      • Features
      • Committee Of Supply (COS) Debate
    • Case Studies
    • Faces of A*STAR
    • National Survey of RIE
    • Connect with Us
  • Career
  • Home
  • News
  • A*STAR News
  • Publicity Highlights
  • A*STAR News
    • Publicity Highlights
    • Press Releases
    • Features
    • Committee Of Supply (COS) Debate
  • Case Studies
  • Faces of A*STAR
  • National Survey of RIE
  • Connect with Us
Agency for Science, Technology and Research (A*STAR)
PartnershipsCareersSuppliersContact UsWhistleblowing
  • Report Vulnerability
  • Privacy Statement
  • Terms & Conditions
    • Publicity Highlights

    Joint lab to improve treatment of liver cancer opened in Biopolis

    03 May 2018
    • Whatsapp
    • Telegram
    • Facebook
    • Twitter
    • Email
    • Linked In

    The PuRPOSE Programme launched its joint laboratory at Biopolis on 30 April 2018 to improve the treatment of liver cancer. The programme is a collaboration between A*STAR’s Institute of Molecular and Cell Biology (IMCB)- A*STAR’s Genome Institute of Singapore (GIS)- the National Cancer Centre Singapore (NCCS)- the National University of Singapore (NUS)- and Samsung Medical Center from South Korea.

    The collaboration is the world’s first clinically reliable and robust patient-specific diagnostic and predictive platform for liver cancer- and brings together leading experts in translational research from Singapore and South Korea.

    Liver cancer is the sixth most common cancer worldwide- and the second most common cause of cancer death . It is also the fourth most common cancer among men in Singapore . If untreated- most patients do not survive beyond 6 months. There are currently few efficacious drugs for treating liver cancer and this poses a huge unmet clinical need.

    The new platform will allow researchers and pharmaceutical companies to work together to understand the disease better- in the hope of accelerating drug development and expanding treatment options for patients.

    Read more below:

    • The Straits Times: Lab to boost treatment of liver cancer launched
    • Lianhe Zaobao: Singapore partners South Korea in liver cancer precision medicine research
    • Channel NewsAsia: Faster- targeted therapy for liver cancer patients
    Related TopicsCancer